With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...

A single copy deletion of RNA polymerase II in colorectal cancer makes the tumors 10 times more sensitive to Heidelberg Pharma's ADCs Heidelberg Pharma's collaborators at the University of Texas MD Anderson Cancer Center have...

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...

Approach Summary Licensing status Publication and contact information Assays & screens RNA sequencing of multiple drug-resistant cells to identify therapeutic targets and mechanisms of action In vitro studies suggest RNA sequencing of drug-resistant cells could...

A Stanford University team has used a computational approach to analyze publicly available gene expression profiles and identified two drug repurposing opportunities. 1,2 The researchers found that the anticonvulsant topiramate could have use in inflammatory...

According to EpiCept, FDA indicated the biotech should compare Ceplene plus IL-2 vs. IL-2 monotherapy using OS as the primary endpoint as part of a registration trial in order to isolate the effect of Ceplene...

A meta-analysis of data from 1,455 AML patients in first complete remission in 6 international trials showed that IL-2 alone did not significantly increase LFS or OS vs. standard of care (p=0.52 and p=0.46, respectively)....

EpiCept said FDA requested the company include an IL-2 monotherapy arm in a planned open-label Phase III trial as part of an application for an SPA. In May, EpiCept submitted a protocol to FDA to...